Xencor, Inc.

XNCR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $125.6M $110.5M $174.6M $164.6M $275.1M $122.7M $156.7M $40.6M
Cost of Revenue — — — — — — — —
Gross Profit — — — — — — — —
Gross Margin — — — — — — — —
Operating Expenses
Research & Development $239.4M $227.7M $253.6M $199.6M $192.5M $169.8M $118.6M $97.5M
SG&A Expense $63.6M $61.2M $53.4M $47.5M $38.8M $29.7M $24.3M $22.5M
Operating Income $-177.5M $-178.4M $-132.4M $-82.5M $43.8M $-76.8M $13.8M $-79.4M
Operating Margin -141.4% -161.5% -75.8% -50.1% 15.9% -62.6% 8.8% -195.5%
Interest Expense — — $6.2M $13.0K $13.0K — — $16.0K
Pretax Income $-89.6M $-234.9M $-119.6M $-54.5M $82.6M $-69.3M $27.2M $-70.4M
Income Tax Expense $2.5M $1.6M $13.7M $673.0K $0 $0 $312.0K $0
Net Income $-91.9M $-232.6M $-133.1M $-55.2M $82.6M $-69.3M $26.9M $-70.4M
Net Margin -73.2% -210.5% -76.2% -33.5% 30.0% -56.5% 17.2% -173.4%
EPS (Basic) $-1.24 $-3.58 $-2.20 $-0.93 $1.42 $-1.21 $0.48 $-1.31
EPS (Diluted) $-1.24 $-3.58 $-2.20 $-0.93 $1.37 $-1.21 $0.46 $-1.31
Shares Outstanding (Basic) 74.2M 65.0M 60.5M 59.7M 58.4M 57.2M 56.5M 53.9M
Shares Outstanding (Diluted) 74.2M 65.0M 60.5M 59.7M 60.5M 57.2M 58.5M 53.9M
Dividends Per Share — — — — — — — —
← Newer Page 1 of 2 Older →